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Abstract 
Background: Studies on diabetic foot and its complications involving a significant and representative sample of 
patients in South American countries are scarce. The main objective of this study was to acquire clinical and epide‑
miological data on a large cohort of diabetic patients from 19 centers from Brazil and focus on factors that could be 
associated with the risk of ulcer and amputation.
Methods: This study presents cross sectional, baseline results of the BRAZUPA Study. A total of 1455 patients were 
included. Parameters recorded included age, gender, ethnicity, diabetes and comorbidity‑related records, previous 
ulcer or amputation, clinical symptomatic score, foot classification and microvascular complications.
Results: Patients with ulcer had longer disease duration (17.2 ± 9.9 vs. 13.2 ± 9.4 years; p < 0.001), and poorer gly‑
cemic control (HbA1c 9.23 ± 2.03 vs. 8.35 ± 1.99; p < 0.001). Independent risk factors for ulcer were male gender (OR 
1.71; 95 % CI 1.2–3.7), smoking (OR 1.78; 95 % CI 1.09–2.89), neuroischemic foot (OR 20.34; 95 % CI 9.31–44.38), region 
of origin (higher risk for those from developed regions, OR 2.39; 95 % CI 1.47–3.87), presence of retinopathy (OR 1.68; 
95 % CI 1.08–2.62) and absence of vibratory sensation (OR 7.95; 95 % CI 4.65–13.59). Risk factors for amputation were 
male gender (OR 2.12; 95 % CI 1.2–3.73), type 2 diabetes (OR 3.33; 95 % CI 1.01–11.1), foot at risk classification (higher 
risk for ischemic foot, OR 19.63; 95 % CI 3.43–112.5), hypertension (lower risk, OR 0.3; 95 % CI 0.14–0.63), region of 
origin (South/Southeast, OR 2.2; 95 % CI 1.1–4.42), previous history of ulcer (OR 9.66; 95 % CI 4.67–19.98) and altered 
vibratory sensation (OR 3.46; 95 % CI 1.64–7.33). There was no association between either outcome and ethnicity.
Conclusions: Ulcer and amputation rates were high. Age at presentation was low and patients with ulcer presented 
a higher prevalence of neuropathy compared to ischemic foot at risk. Ischemic disease was more associated with 
amputations. Ethnical differences were not of great importance in a miscegenated population.
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Background
The rising prevalence of diabetes around the world has 
dramatically increased the number of people bearing 
complications of this potentially incapacitating disease 
[1]. Peripheral neuropathy and diabetic foot are among 
the most feared. They frequently terminate in ulcer, 
infection and amputation, significantly reducing qual-
ity of life [2]. The life expectancy of a person with lower 
limb amputation is comparable to that of other serious 
diseases, such as aggressive types of cancer or advanced 
congestive heart failure [3, 4].
Additionally, it is estimated that one person undergoes 
amputation every 20 s around the globe as a complication 
of diabetes and that up to 85 % of these procedures could 
be prevented with adequate screening [5].
The incidence of diabetes is rising more rapidly in 
developing regions such as Latin America and South-
east Asia than in Western Europe or North America [1, 
6], putting a serious economic burden on the healthcare 
budgets of these nations. Given the disparities in health 
care access and the social, economic and ethnic differ-
ences between these regions, it is crucial to gain knowl-
edge of the clinical characteristics and epidemiology of 
foot at risk in different areas of the world.
Additionally, several studies have highlighted the dis-
similarities in diabetes incidence, management, preva-
lence and metabolic control, as well as risk and clinical 
evolution of foot complications [7, 8]. Studies on foot 
ulcers involving a significant and representative sam-
ple of patients such as the EURODIALE cohort [9] are 
scarce, especially in developing regions. In Brazil, in 
addition to the lack of descriptive data on foot at risk and 
ulcer prevalence, there are great dissimilarities between 
different regions regarding access to health care and soci-
oeconomical structure that could lead to different pres-
entations of foot at risk and diabetic foot complications.
Therefore, our aims were to acquire data on the clinical 
and epidemiological characteristics of a large cohort of 
patients from several centers in our country, all special-
izing in the evaluation and care of patients with diabetes 
and focus on factors that could be associated with the 
risk of ulcer and amputation.
Methods
This study presents cross sectional, baseline results of 
the Brazilian Cooperative Study on Ulcer, Severe Periph-
eral Neuropathy and Amputation (BRAZUPA), which is 
funded by the National Institute of Science and Technol-
ogy—Obesity and Diabetes Division, in order to gather 
data on the current situation of foot at risk throughout 
the nation. One thousand fifty-five consecutive patients 
referred for evaluation of foot at risk to 19 different spe-
cialized diabetic centers in the country were included in 
the study. Among these, six included diabetic foot care 
units and the others started to structure theirs after the 
study beginning. Patients were referred from primary 
care facilities according to Brazilian National Health Sys-
tem (SUS) standard proceedings. All data were collected 
between June 2012 and July 2014 and each center submit-
ted data collected during the first year after study entry. 
The four most populous of the country’s five administra-
tive regions were included, and the data can be consid-
ered representative for the whole country (around 200 
million people at the time the study was initiated)—Fig. 1. 
Trained personnel collected data during patients’ routine 
evaluations and from the medical records of each institu-
tion. Data were collected on a standardized electronic sheet 
developed during a 6-month long pilot study involving 
14 centers, simplified to allow input without compromis-
ing the routine care of patients. Dedicated personnel were 
trained in each center during the pilot study. The data col-
lected was submitted to the coordinating center at the end 
of the first year (University of Campinas, Campinas, Sao 
Paulo, Brazil), where it was analyzed as a whole after all 
centers had submitted their information. Patient character-
istics recorded included age, gender, ethnicity (white Latin, 
African descent, mixed ethnicity and Asian), diabetes and 
Fig. 1 Geographical distribution of the centers
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comorbidity related records, previous ulcer or amputation, 
symptom characteristics and clinical symptomatic score.
Foot at risk was classified as without risk, neuropathic, 
ischemic or neuroischemic. Neuropathy was defined as a 
positive result in clinical or symptomatic scores and/or 
an abnormal sensitivity test using a 10 g Semmes–Wein-
stein monofilament. Vibratory sensation was classified 
as present, diminished or absent according to the results 
of the 128  Hz tuning fork examination [5]. Ischemia 
was defined as diminished or absent pedal pulses or 
decreased ankle-brachial pressure index (ABI  <  0.9) [5, 
10]. Amputations were classified as minor (below the 
ankle) or major (ankle or higher). Ulcers were evaluated 
for their prevalence and etiological origin: ischemic, neu-
ropathic or neuro-ischemic.
The presence of other microvascular complications 
was also evaluated. Retinopathy was assessed by standard 
fundoscopy by a trained ophthalmologist at each center 
and nephropathy by the presence of microalbuminuria 
and/or abnormal creatinine clearance (calculated using 
the Cockroft-Gault formula). Visual impairment was 
defined as abnormal Snellen chart test result despite the 
use of corrective lenses. Renal impairment was defined as 
creatinine clearance <60 ml/min/1.73 m2.
The study was approved by each institution’s ethics in 
research committee as well as by the coordinating cent-
er’s Ethics Committee.
Statistical analysis
Categorical data is shown as percentages; continuous 
variables as means (standard deviation—SD).
Comparison between groups of categorical data was made 
using the Chi Square test. Differences in continuous vari-
ables between two groups were evaluated by Student’s t test.
Independent risk factors for ulcer and amputation 
were assessed by multiple logistic regression analysis. 
The model for ulcer included age, gender, type of dia-
betes, disease duration, ethnicity, BMI, smoking status, 
foot at risk classification (foot without risk as reference 
category), vibratory sensation, visual impairment, hyper-
tension, renal impairment and macro region of ori-
gin. Adjustments were done by the forward conditional 
method. The model for amputation included all of the 
abovementioned variables with the addition of history of 
previous ulcer episode.
Statistical analysis was performed with SPSS ver-
sion 20.0 (IBM Inc.). Significance was defined as a 
p value <0.05.
Results and discussion
Patient characteristics
Baseline patient characteristics are summarized 
in Table  1. The mean age and disease duration of 
Table 1 Clinical and  epidemiological characteristics of   
study participants
Variable Mean (SD)/%
Age 57.7 (14.2)
Sex (female/male) 58.6/41.4
BMI (kg/m2) 29.3 (6.2)
Ethnicity
 White 53.8
 Black 18.4
 Mixed 20.8
 Asian 7.0
Type of diabetes (1/2) 9.3/90.7
Diabetes duration (years) 14.2 (9.8)
HbA1c (%) 8.56 (2.03)
Smoking 24.2
Hypertension 81.5
Cardiopathy 28.5
Dyslipidemia 72.9
Nephropathy
 Stage 1 52.1
 Stage 2 25.4
 Stage 3 15.8
 Stage 4 1.9
 Stage 5 4
Retinopathy 46.2
Visual impairment 50.3
Previous ulcer 25.3
Active ulcer 18.6
Amputation 13.7
 Minor 82.7
 Major 17.3
Foot at risk classification
 Foot without risk 37.8
 Neuropathic 33.7
 Ischemic 8.5
 Neuroischemic 20
Vibratory sensation
 Normal 55.7
 Diminished 29.9
 Absent 14.5
Score of symptoms
 Normal 20.4
 Mild 29.6
 Moderate 28.1
 Severe 22
Treatment of neuropathy (yes) 14.1
Region
 South 18.9
 Southeast 38.9
 Midwest 3.4
 Northeast 38.8
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participants was 57.67 (14.23) years and 14.21 (9.77) 
years, respectively. The majority of patients were female 
(58.6 %), White (53.8 %) and had type 2 diabetes (90.7 %). 
Nearly a quarter (25.3 %) of patients had a previous his-
tory of ulcer and 13.7 % of amputation (17.3 % of these 
were major amputations). One in every twenty patients 
(5.3 %) had undergone more than one amputation proce-
dure. One-third of patients had neuropathic foot (33.7 %) 
and only 8.5  % had ischemic disease alone. Nearly one-
fifth (18.6 %) of all evaluated patients presented a current, 
active foot ulcer at evaluation.
Differences between patients with and 
without amputation, ulcer and mild versus moderate/
severe neuropathy
Ulcer
We observed a significantly larger proportion of men 
with a previous history of ulcer (35.7 vs. 18 %; p < 0.001). 
These patients also had longer disease duration 
(17.2 ±  9.9 vs. 13.2 ±  9.4  years; p  <  0.001), and poorer 
glycemic control (HbA1c 9.23  ±  2.03 vs. 8.35  ±  1.99; 
p  <  0.001). Those of White or Mixed ethnicities had a 
higher proportion of ulcer than Black and Asian eth-
nicities (29 and 24.6 vs. 19.7 and 16.5  %, respectively; 
p  =  0.008). There was a higher prevalence of previ-
ous ulcer in those with retinopathy (38.3 vs. 14.1  %; 
p  <  0.001), visual (30.8 vs. 18  %; p  <  0.001) and renal 
impairment (34.8 vs. 22.7  %; p  <  0.001). Ulcer was less 
common in patients with ischemic foot than neuro-
pathic or neuro-ischemic classifications (14.2 vs. 39.3 
and 45.1 %, respectively; p < 0.001). Individuals from the 
economically developed regions (South/Southeast) had 
a higher prevalence of previous ulcer episode than those 
coming from economically emerging ones (Midwest/
Northeast) (28.8 vs. 20.7 %, respectively; p = 0.001).
Table 2 shows the prevalence of different clinical char-
acteristics in patients with and without ulcers.
Amputation
A significantly higher proportion of men were amputated 
compared to women (23.5 vs. 6.5  %; p  <  0.001). Older 
patients (60.5  ±  10.8 vs. 57.3  ±  14.6  years; p  <  0.001) 
and those with longer disease duration (17.3 ±  10.4 vs. 
13.6 ± 9.5 years; p < 0.001) had also a higher prevalence 
of amputation, as did patients with type 2 diabetes (14.4 
vs. 6.6  %; p  =  0.017). Patients of Asian descent were 
less frequently amputated than those of White, Black 
or Mixed ethnicities (7.6  % vs. 16.5, 10.8 and 12.2  %, 
respectively; p  =  0.043). Those with retinopathy also 
had a higher prevalence of amputation (20.5 vs. 7.5  %; 
p  <  0.001), as did patients with visual (17.1 vs. 9.2  %; 
p < 0.001) or renal impairment (18.4 vs. 9.9 %; p = 0.001). 
Similar to what was found for ulcer, patients classified as 
having ischemic foot had a lower prevalence of amputa-
tion than those with neuropathic and neuroischemic foot 
(9.6 vs. 20.6 and 28.7 %, respectively; p < 0.001). Patients 
with hypertension also had a lower prevalence of ampu-
tation (12 vs. 20.4 %; p < 0.001).
Table 3 shows the prevalence of clinical characteristics 
in patients with and without amputation.
Moderate/severe neuropathic symptoms
In the analysis of patients with moderate/severe vs. nor-
mal/mild neuropathic symptom scores, those with higher 
(more severe) scores were more frequently female (53 vs. 
45.8 %; p = 0.01), older (58.5 ± 13 vs. 56.4 ± 15.5 years; 
p  =  0.009) and had a higher BMI (29.95  ±  6.58 vs. 
28.92  ±  5.79; p  =  0.004). White patients were less fre-
quently classified as having severe symptoms than those 
of Black, Mixed or Asian ethnicities (45.8 vs. 52.9, 54.5 
and 57 %, respectively; p = 0.02). Patients with retinopa-
thy had a higher prevalence of severe symptoms (52.7 vs. 
45.8  %; p  =  0.02), as did those with visual impairment 
(54.1 vs. 46.1 %; p = 0.006). In contrast to what was found 
for amputation and ulcer, patients from the emerging 
regions had a higher prevalence of severe symptoms than 
those coming from developed regions (57.3 vs. 44.9  %, 
respectively; p < 0.001).
Table  4 shows the prevalence of clinical characteris-
tics in patients with normal/mild and moderate/severe 
symptoms.
Independent risk factors for ulcer and amputation
Multivariate regression analyses are summarized in 
Table 5. Independent risk factors for ulcer were male gen-
der, smoking, foot at risk classification (highest risk asso-
ciated with the neuroischemic group and lowest to the 
ischemic group), region of origin (higher risk for those 
from more economically developed regions), presence of 
retinopathy and absent vibratory sensation. Risk factors 
for amputation were male gender, type 2 diabetes, foot at 
risk classification (higher risk for ischemic foot), hyper-
tension (lower risk), region of origin (South/Southeast), 
previous history of ulcer and altered vibratory sensation. 
There was no association between the two outcomes and 
ethnicity in multivariate analyses.
This is the first large, comprehensive multicenter epi-
demiological study of foot at risk in diabetes outside 
Europe [9], Australia [11] or China [12]. We found the 
prevalence of previous ulcer to be 25 and 14 % for ampu-
tation. Additionally, 18 % of patients had an active ulcer 
at the time of evaluation. Although at a first glance the 
rate of active foot ulcers could be considered high when 
compared to the results of other studies (e.g. the FREE-
MANTLE Study) [11], there are some important differ-
ences. Our results are, at this time, from a transversal 
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study and not prospectively evaluated. Additionally, the 
inclusion of centers with structured foot care units could 
have contributed to increase active ulcer prevalence. In 
the next years, in a prospective basis it will be possible to 
determine with more certainty if the prevalence of ulcers 
in patients with diabetes in Brazil is higher than in other 
parts of the world.
Fifty percent had moderate/severe neuropathic symp-
toms. These findings are in line with previous data [13, 
14], especially that from developing nations [15, 16], 
except for the high proportion of patients with severe 
symptoms. Also noteworthy, despite the high number of 
patients with symptoms, we found that only 14  % were 
receiving medication for neuropathic pain relief.
Our patients had a unique combination of character-
istics. The major difference between our patients and 
those evaluated in studies from the USA [17] or Western 
Europe [18] is a higher proportion of patients with neu-
ropathic disease, with clear predominance of the neuroi-
schemic population, and a smaller number of patients 
with isolated ischemic disease. Most studies conducted 
in economically developed nations show a high preva-
lence of ischemic disease [19, 20]. Similar findings had 
been found in one of the centers involved in our study, 
Table 2 Prevalence (%) and  means of  clinical characteris-
tics in patients with and without previous ulcer
Variable Previous ulceration p
Yes No
Age (years) 58.4 57.5 0.26
Sex (female/male) 41.7/58.3 64.4/35.6 <0.001
BMI (kg/m2) 29.4 29.3 0.88
Ethnicity 0.008
 White 61.2 51.2
 Black 14.4 20.1
 Mixed 20 20.9
 Asian 4.4 7.8
Type of diabetes (1/2) 9.9/90.1 9.4/90.6 0.77
Diabetes duration (years) 17.2 13.2 <0.001
HbA1c (%) 9.23 8.35 <0.001
Smoking (yes) 25.8 22.7 0.25
Hypertension (yes) 80.3 82 0.49
Cardiopathy (yes) 39.5 24.4 <0.001
Dyslipidemia (yes) 71.2 73.5 0.45
Nephropathy (ClCr < 60 ml/min) 29.6 18.8 <0.001
Retinopathy (yes) 69.8 38 <0.001
Visual impairment (yes) 63.3 46.1 <0.001
Foot at risk classification <0.001
 Foot without risk 7.9 48.6
 Neuropathic 52.3 27.2
 Ischemic 4.8 9.9
 Neuroischemic 35 14.3
Score of symptoms 0.44
 Normal/mild 47.3 49.9
 Moderate/severe 52.7 50.1
Disability score <0.001
 Normal/mild 53.1 80.5
 Moderate/severe 46.9 19.5
Treatment of neuropathy (yes) 17.3 11.9 0.015
Region 0.001
 South/Southeast 65.1 54.6
 Northeast/Midwest 34.9 45.4
Table 3 Prevalence (%) and  means of  clinical characteris-
tics in patients with and without previous amputation
Variable Previous amputation p
Yes No
Age (years) 60.5 57.3 0.001
Sex (female/male) 29.1/70.9 63.3/36.7 <0.001
BMI (kg/m2) 28.7 29.4 0.18
Ethnicity 0.043
 White 63.3 51.7
 Black 14.8 19.6
 Mixed 18.1 21.1
 Asian 3.8 7.7
Type of diabetes (1/2) 4.2/95.8 9.5/90.5 0.017
Diabetes duration (years) 17.3 13.6 <0.001
HbA1c (%) 8.76 8.54 0.4
Smoking (yes) 26.1 23.9 0.52
Hypertension (yes) 72.2 83 0.001
Cardiopathy (yes) 36.4 26.8 0.023
Dyslipidemia (yes) 65 74.3 0.022
Nephropathy (ClCr < 60 ml/min) 33.3 19.7 0.001
Retinopathy (yes) 69.8 42.1 <0.001
Visual impairment (yes) 65 47.7 <0.001
Foot at risk classification <0.001
 Foot without risk 3.3 43.9
 Neuropathic 49.5 30.6
 Ischemic 6 9.1
 Neuroischemic 41.2 16.4
Score of symptoms 0.7
 Normal/mild 47.9 49.5
 Moderate/severe 52.1 50.5
Disability score <0.001
 Normal/mild 39.1 79.2
 Moderate/severe 60.9 20.8
Treatment of neuropathy (yes) 19.3 11.5 0.005
Region 0.069
 South/Southeast 62.4 55.4
 Northeast/Midwest 37.6 44.6
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but with a higher proportion of isolated neuropathic dis-
ease [21]. Mean age (57 years old) was also younger than 
that reported for patients from Western Europe [22] and 
North America [23]. On the other hand, characteristics 
like longer disease duration and high frequency of associ-
ated comorbidities are in line with data from developed 
nations [18–23].
Individuals with more severe symptoms were more 
commonly overweight, older and female. The relation 
between BMI and symptoms of neuropathy could be asso-
ciated with other obesity related comorbidities or with 
excessive load on the lower extremities. Ulcer and ampu-
tation were less common in patients of Asian descent, a 
fact already reported in other studies [24]. However, in 
multiple adjusted regressions, ethnicity was not a fac-
tor associated with either outcome. We believe that this 
is due to the historic and strong miscegenation typical of 
our country’s population. Social and economic factors are 
probably more associated with these ethnic differences in 
terms of the prevalence of ulcer and amputation [25].
Indeed, ulcer and amputation were more common in 
the more developed regions of the country, which may 
be related to the greater prevalence of other diseases 
such as obesity and metabolic syndrome [26]. Also, social 
and economic differences might play an important role, 
in conjunction with disparities in health care access. 
Increased awareness by health care professionals and 
more swiftly available access to specialty centers could 
result in increased diagnosis, which in turn is reflected in 
an increase in apparent prevalence. Additionally, diabetes 
prevalence is higher in the South and Southeast regions 
of the country [27].
Regarding factors independently associated with ulcer 
risk, the finding that men have an increased risk of ulcer 
is in accord with the great majority of previous studies 
[9, 11, 12, 21, 22, 25]. This fact is associated with disease 
progression and also with social facts related to men 
being more frequently family providers and consequently 
showing lower adherence to medical visits and wound 
care [28].
Table 4 Prevalence (%) and  means of  clinical character-
istics in  patients with  normal/mild and  moderate/severe 
symptoms
Variable Score of symptoms p
Normal/mild Moderate/severe
Age (years) 56.4 58.5 0.009
Sex (female/male) 56/63 44/37 0.01
BMI (kg/m2) 28.9 29.9 0.004
Ethnicity 0.024
 White 58 49.8
 Black 16.9 19.2
 Mixed 18.4 22.4
 Asian 6.7 8.5
Type of diabetes (1/2) 10.3/89.7 7.9/92.1 0.12
Diabetes duration (years) 13.9 14.4 0.3
HbA1c (%) 8.66 8.46 0.26
Smoking (yes) 25.2 25.4 0.94
Hypertension (yes) 80.1 84.1 0.063
Cardiopathy (yes) 26.4 30.9
Dyslipidemia (yes) 71.1 75 0.15
Nephropathy (ClCr < 60 ml/
min)
22.4 21.5 0.48
Retinopathy (yes) 42.3 49.1 0.024
Visual impairment (yes) 46.1 54.1 0.006
Foot at risk classification <0.001
 Foot without risk 53.8 27.1
 Neuropathic 19.4 41.4
 Ischemic 11.2 5.8
 Neuroischemic 15.5 25.7
Previous ulceration (yes) 22.3 24.2 0.44
Previous amputation (yes) 12.6 13.3 0.7
Treatment of neuropathy 
(yes)
11.4 17.9 0.003
Region <0.001
 South/Southeast 64.2 52.1
 Northeast/Midwest 35.8 47.9
Table 5 Multivariate regression analyses of  factors influ-
encing the risk of ulcer and amputation
Factor OR 95 % CI p
Ulcer
 Male sex 1.71 1.12; 2.59 0.011
 Smoking 1.78 1.09; 2.89 0.019
 Neuropathic foot 9.96 4.85; 20.43 <0.001
 Ischemic foot 5.64 1.9; 16.7 0.002
 Neuroischemic foot 20.34 9.31; 44.38 <0.001
 Decreased vibratory sensation 1.36 0.82; 2.24 0.23
 Absent vibratory sensation 7.95 4.65; 13.59 <0.001
 Retinopathy 1.68 1.08; 2.62 0.022
 Region (South/Southeast) 2.39 1.47; 3.87 <0.001
Amputation
 Male sex 2.12 1.2; 3.73 0.009
 Type 2 diabetes 3.33 1.01; 11.1 0.049
 Neuropathic foot 5.8 1.25; 26.9 0.025
 Ischemic foot 19.63 3.43; 112.5 0.001
 Neuroischemic foot 11.6 2.43; 55.33 0.002
 Decreased vibratory sensation 2.4 1.09; 5.3 0.03
 Absent vibratory sensation 3.46 1.64; 7.33 0.001
 Hypertension 0.3 0.14; 0.63 0.002
 Region (South/Southeast) 2.2 1.1; 4.42 0.027
 Previous ulcer (yes) 9.66 4.67; 19.98 <0.001
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Loss of vibratory sensation and large fiber damage are 
frequently seen as the first sensations affected by distal 
diabetic polineuropathy [29]. Retinopathy is also a long-
term complication of diabetes and is expected to co-exist 
with neuropathy. In addition, it can make self-care and 
self-examination more difficult and thus predispose to 
ulcer. In adjusted analysis, however, visual impairment 
was not an associated risk factor, indicating that micro-
vascular processes occurring simultaneously is a more 
likely explanation for ulcer than visual deficits.
The lowest risk for ulcer relative to foot at risk classifi-
cation when compared to foot without risk was isolated 
arterial disease. The greatest risk was linked to neuroi-
schemic disease. The combination of neuropathy and 
peripheral arterial disease has been associated with a 
high ulcer risk in most previous studies [9, 11, 21], but 
ischemia is normally associated with a greater risk than 
neuropathy [9, 30]. This difference might be due to neu-
ropathy being more common in developing countries. 
Similar findings have been published in smaller studies 
from other emerging nations [12, 15, 16, 21]. A younger 
age at presentation and a lower prevalence of obesity and 
other associated diseases apart from diabetes itself may 
combine to expose patients to ulcer sooner than athero-
sclerotic disease manifests.
As reported for ulcer, male sex is associated with a 
greater risk of amputation in almost all studies on dia-
betic foot complications. In the case of type 2 diabetes, 
it is more commonly associated with other comorbidities 
that can predispose to poorer outcomes in ulcer, such as 
obesity, insulin resistance, dyslipidemia and atheroscle-
rosis [31], thus explaining the greater risk of amputation, 
even in a younger population. Loss of vibratory sensation 
and previous ulcer are established risk factors for ampu-
tation. Amputation is, in fact, a last resort treatment for 
diabetic ulcers.
Unlike ulcer, patients presenting ischemic disease, 
either in an isolated form or associated with neuropathy 
presented the greatest risk for amputation in multivariate 
analysis. Ischemic disease has frequently been associated 
with poorer ulcer outcomes [9, 11], especially when asso-
ciated with infection [32], explaining the higher probabil-
ity of ending in amputations. The finding of hypertension 
being associated with a lower risk for amputation even 
in adjusted analysis was a surprising one, and no clear 
explanation could be found for this fact with the cur-
rent data. Follow up results may cast some light on this 
matter.
This study has some limitations. The data represent 
baseline information, and the causative factors here iden-
tified have the constrictions inherent to cross sectional 
evaluations. However, all the risk factors found for ulcer 
and amputation are well recognized in the literature, 
which makes us more confident that our estimates are 
adequate. Another limitation is that we found a relatively 
high number of patients referred for evaluation who 
in the end were revealed to present foot without risk. 
Although serving as a reference category to estimate the 
risk of neuropathy vs. ischemia for ulcer and amputation, 
the relatively small number of patients with foot at risk 
could have underpowered our analysis. Nevertheless, 
we were able to identify several risk factors associated 
with those conditions, a detail that reassures us that the 
analysis deserves merit. Additionally, our population was 
a large one, and the fact that patients came from several 
different centers and were primary care referrals support 
the representativeness of our sample. As with any other 
studies using ABI for ischemic disease diagnosis, the 
prevalence of ischemic disease could have been under-
represented, but this methodology has been used in most 
studies; therefore, data from this study is comparable 
to that in others. Whether our findings can be extrapo-
lated to other South or Latin American populations is 
also debatable as our country bears significant ethnic and 
social differences from others in this region of the world.
Conclusions
In conclusion, we found a high prevalence of ulcer and 
amputation in patients with foot at risk in Brazil. Addi-
tionally, we found a younger age at presentation and 
that patients with ulcer presented a higher prevalence of 
neuropathy compared to ischemic foot at risk. Ischemic 
disease remains a factor associated with amputations, 
probably as a determinant of poorer ulcer outcomes, as 
reported in other studies. Ethnic differences were not 
of great importance in a miscegenated population, and 
probably only reflect social and economic differences as 
well as health care access disparities. We hope the data 
presented here can contribute to the fast growing litera-
ture on diabetic foot and to understanding regional dif-
ferences in factors affecting the prevalence of ulcer and 
amputation. This study will continue to follow up patients 
presenting with ulcer and data on their outcomes are 
expected in the next couple of years.
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